A Randomized, Open-label Study of the Effect of Intermittent Xeloda in Combination With Eloxatin, Versus Fluorouracil/Leucovorin, on Disease-free Survival in Patients Who Have Undergone Surgery for Colon Cancer

Trial Profile

A Randomized, Open-label Study of the Effect of Intermittent Xeloda in Combination With Eloxatin, Versus Fluorouracil/Leucovorin, on Disease-free Survival in Patients Who Have Undergone Surgery for Colon Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Capecitabine (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colon cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms XELOXA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Jan 2016 Results of pooled analysis of five studies (C-07, C-08, N0147, MOSAIC and XELOXA) published in the Journal of Clinical Oncology
    • 28 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top